Your browser doesn't support javascript.
loading
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya, Irati; Roman, Marta; Welch, Connor; Entrialgo-Cadierno, Rodrigo; Salmon, Marina; Santos, Alba; Feliu, Iker; Kovalski, Joanna; Lopez, Ines; Rodriguez-Remirez, Maria; Palomino-Echeverria, Sara; Lonfgren, Shane M; Ferrero, Macarena; Calabuig, Silvia; Ludwig, Iziar A; Lara-Astiaso, David; Jantus-Lewintre, Eloisa; Guruceaga, Elizabeth; Narayanan, Shruthi; Ponz-Sarvise, Mariano; Pineda-Lucena, Antonio; Lecanda, Fernando; Ruggero, Davide; Khatri, Purvesh; Santamaria, Enrique; Fernandez-Irigoyen, Joaquin; Ferrer, Irene; Paz-Ares, Luis; Drosten, Matthias; Barbacid, Mariano; Gil-Bazo, Ignacio; Vicent, Silve.
Afiliação
  • Macaya I; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Roman M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Welch C; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA.
  • Entrialgo-Cadierno R; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Salmon M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Santos A; Experimental Oncology Group, Molecular Oncology Program, Spanish National Cancer Center (CNIO), Madrid, Spain.
  • Feliu I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Kovalski J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Lopez I; H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Rodriguez-Remirez M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Palomino-Echeverria S; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Lonfgren SM; Department of Urology, University of California San Francisco, San Francisco, CA, USA.
  • Ferrero M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Calabuig S; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.
  • Ludwig IA; Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra, Pamplona, Spain.
  • Lara-Astiaso D; Stanford Institute for Immunity, Transplantation and Infection, Stanford, CA, USA.
  • Jantus-Lewintre E; Stanford Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA, USA.
  • Guruceaga E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Narayanan S; Molecular Oncology Laboratory, Fundación Para La Investigación del Hospital General Universitario de Valencia, Valencia, Spain.
  • Ponz-Sarvise M; Mixed Unit TRIAL (Principe Felipe Research Centre & Fundación para la Investigación del Hospital General Universitario de Valencia), Valencia, Spain.
  • Pineda-Lucena A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Lecanda F; Molecular Oncology Laboratory, Fundación Para La Investigación del Hospital General Universitario de Valencia, Valencia, Spain.
  • Ruggero D; Mixed Unit TRIAL (Principe Felipe Research Centre & Fundación para la Investigación del Hospital General Universitario de Valencia), Valencia, Spain.
  • Khatri P; Department of Pathology, Universitat de Valencia, Valencia, Spain.
  • Santamaria E; University of Navarra, Center for Applied Medical Research, Molecular Therapies Program, Pamplona, Spain.
  • Fernandez-Irigoyen J; University of Navarra, Center for Applied Medical Research, Genomics Platform, Pamplona, Spain.
  • Ferrer I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Paz-Ares L; Molecular Oncology Laboratory, Fundación Para La Investigación del Hospital General Universitario de Valencia, Valencia, Spain.
  • Drosten M; Mixed Unit TRIAL (Principe Felipe Research Centre & Fundación para la Investigación del Hospital General Universitario de Valencia), Valencia, Spain.
  • Barbacid M; Department of Pathology, Universitat de Valencia, Valencia, Spain.
  • Gil-Bazo I; University of Navarra, Center for Applied Medical Research, Bioinformatics Platform, Pamplona, Spain.
  • Vicent S; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Nat Commun ; 14(1): 6332, 2023 10 10.
Article em En | MEDLINE | ID: mdl-37816716
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Limite: Humans Idioma: En Revista: Nat Commun Assunto da revista: BIOLOGIA / CIENCIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha